Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AZTR

Azitra Inc

Dec 11 • 04:00PM ET

0.4963

Dollar change +0.0053
Percentage change 1.08	%

Healthcare • Biotechnology • USA • AMEX

Peers: ANAB FATE VYGR AKTX CARA ARWR ORMP PULM ARMP BCRX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.36	Insider Own	1.87%	Shs Outstand	7.63M	Perf Week	0.06%
Market Cap	3.79M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	0.00%	Shs Float	7.48M	Perf Month	-4.92%
Income	-9.03M	PEG	-	EPS next Q	-0.31	Inst Own	2.07%	Short Float	2.88%	Perf Quarter	-15.16%
Sales	0.10M	P/S	37.87	EPS this Y	96.27%	Inst Trans	-	Short Ratio	1.01	Perf Half Y	-89.07%
Book/sh	1.06	P/B	0.47	EPS next Y	64.39%	ROA	-104.57%	Short Interest	0.22M	Perf Year	-98.70%
Cash/sh	0.95	P/C	0.52	EPS next 5Y	-	ROE	-134.85%	52W Range	0.43 - 68.40	Perf YTD	-98.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-107.36%	52W High	-99.27%	Beta	-1.40
Dividend TTM	-	Quick Ratio	5.58	Sales past 5Y	149.87%	Gross Margin	-352.29%	52W Low	16.39%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	5.58	EPS Y/Y TTM	-	Oper. Margin	-11416.44%	RSI (14)	49.48	Volatility	4.36% 6.28%
Employees	10	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-9259.63%	Recom	1.00	Target Price	3.50
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	96.40%	Payout	-	Rel Volume	0.36	Prev Close	0.49
Sales Surprise	-	EPS Surprise	59.04%	Sales Q/Q	-100.00%	Earnings	Nov 12 AMC	Avg Volume	214.04K	Price	0.50
SMA20	2.62%	SMA50	-2.11%	SMA200	-83.77%	Trades		Volume	76,760	Change	1.08%

Nov-12-24 05:05PM	Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates (PR Newswire)
Oct-29-24 09:00AM	Azitra to Present at BIO-Europe 2024 (Business Wire)
Oct-11-24 09:00AM	Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-24-24 08:00AM	Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress (Business Wire)
Sep-18-24 09:00AM	Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors (Business Wire) +5.82%
04:30PM	Loading…
Sep-06-24 04:30PM	Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-28-24 08:30AM	Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire)
Aug-22-24 09:00AM	Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors (Business Wire) +11.14%
Aug-20-24 04:15PM	Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire) +5.98%
Aug-12-24 06:23PM	Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates (Business Wire)
Jul-25-24 05:57PM	CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering (Business Wire) -9.65%
Jul-23-24 09:20PM	Azitra, Inc. Announces Pricing of $10.0 Million Public Offering (Business Wire) +206.79% -76.46%
08:00AM	Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents (Business Wire)
Jun-27-24 04:05PM	Azitra, Inc. Announces Reverse Stock Split (Business Wire) +12.72% -30.15%
May-31-24 08:00AM	Azitra, Inc. Announces Presentation at the 2024 BIO International Convention (Business Wire)
08:00AM	Loading…
May-17-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting (Business Wire) -8.22%
May-10-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting (Business Wire) -13.08%
May-09-24 05:00PM	Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates (Business Wire)
Apr-22-24 04:30PM	Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting (Business Wire) +18.77%
Apr-18-24 04:15PM	Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024 (Business Wire) -5.10%
Mar-15-24 04:15PM	Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-16-24 04:05PM	Azitra, Inc. Announces Closing of Public Offering (Business Wire) +6.01% +5.79%
Feb-13-24 10:09PM	Azitra, Inc. Announces Pricing of Public Offering (Business Wire) -24.33% -73.91%
Jan-16-24 09:00AM	Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US (Business Wire) +32.50%
Jan-03-24 09:00AM	Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference (Business Wire) +11.42%
Nov-14-23 04:30PM	Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates (Business Wire)
Oct-16-23 08:00AM	Azitra to Present at the ThinkEquity Conference (Business Wire) +7.59%
Aug-29-23 08:00AM	Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 04:05PM	Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates (PR Newswire) -6.52%
Jul-19-23 04:05PM	Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors (PR Newswire)
04:05PM	Loading…
Jul-11-23 04:05PM	Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer (PR Newswire)
Jun-21-23 06:46PM	Azitra, Inc. Announces Closing of Initial Public Offering (PR Newswire) +9.62%
Jun-15-23 07:04PM	Azitra, Inc. Announces Pricing of Initial Public Offering (PR Newswire)

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KDT VENTURES FUND I, LP	Former Director	Sep 13 '24	Proposed Sale	0.58	9,730	5,648		Sep 16 05:47 PM
Staskey Norm	Chief Financial Officer	Mar 29 '24	Buy	0.21	47,600	10,034	51,100	Apr 01 09:51 PM
Whitfill Travis	Chief Operating Officer	Feb 13 '24	Buy	0.30	15,000	4,500	334,500	Feb 15 08:42 PM
Staskey Norm	Chief Financial Officer	Feb 13 '24	Buy	0.30	3,300	990	3,500	Feb 15 08:39 PM
Salva Francisco D.	President and CEO	Feb 13 '24	Buy	0.30	333,300	99,990	338,300	Feb 15 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZTR

Azitra Inc

Upgrade your FINVIZ experience